Ortac 150 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Ranitidine hydrochloride |
| Company | Orion pharma ltd |
| Also available as |
Indications
- Treatment of active duodenal ulcer
- Benign gastric ulcer
- Treatment & prevention of ulcer associated with non-steroidal anti-inflammatory agent
- Post operative stress ulcer
- Zollinger-Ellison Syndrome
- Gastroesophageal reflux disease (GERD)
- Gastro-intestinal haemorrhage from stress ulcer in seriously ill patient
- Recurrent haemorrhage in patients with bleeding peptic ulcer
- Before general anesthesia in patient considered to be at risk of acid aspiration particularly obstetric patients
Pharmacology
Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
Dosage & Administration
- 150 mg twice daily for active duodenal and benign gastric ulcers
- 300 mg once daily at night for duodenal and gastric ulcers
- 150 mg twice daily for reflux esophagitis
- 300 mg at bedtime for reflux esophagitis
- 150 mg 3 times daily for Zollinger Ellison syndrome
- Up to 6 g daily in divided doses for Zollinger Ellison syndrome
- 150 mg twice daily for episodic dyspepsia
- 300 mg at bedtime for episodic dyspepsia
- 150 mg at night for maintenance
- 2-4 mg/kg twice daily for children with peptic ulcer
- 50 mg intravenous injection every 6 to 8 hours
- 25 mg per hour for two hours for intermittent intravenous infusion
- 50 mg (2 ml) intramuscular injection every 6 to 8 hours
- 50 mg intramuscular or slow intravenous injection for patients at risk of aspiration syndrome
- 2 mg/kg to 4 mg/kg twice daily for children with peptic ulcer
Interaction
Delayed absorption and increased peak serum concentration with propantheline bromide. Minimal inhibition of hepatic metabolism of coumarin anticoagulants, theophylline, diazepam and propanolol. May alter absorption of pH-dependent drugs (e.g. ketoconazole, midazolam, glipizide). Reduced bioavailability with antacids.
Contraindications
Patients hypersensitive to Ranitidine
Side Effects
- Altered bowel habit
- Dizziness
- Rash
- Tiredness
- Reversible confusional states
- Headache
- Decreased blood counts
- Muscle or joint pain
Pregnancy & Lactation
- Ranitidine crosses the placenta with no evidence of impaired fertility or harm to the fetus
- Caution should be exercised when administered to nursing mothers
Precautions & Warnings
Reduced dosage for patients with impaired renal and hepatic function
Use in Special Populations
Similar healing rates in elderly patients compared to younger patients with no difference in adverse effects
Overdose Effects
No particular problems expected following overdosage. Symptomatic and supportive therapy may be given as appropriate.
Therapeutic Class
H2 receptor antagonist
Reconstitution
- Ortac 50 mg diluted for slow IV inj, intermittent slow IV infusion, continuous IV infusion, and patients with hypersecretory conditions
Storage Conditions
Store in a cool and dry place, protect from light